Stocks · News reference

TD Cowen Maintains Hold on DarioHealth, Lowers Price Target to $8

Aug 12, 2026, 3:17 PMBenzinga Newsdesk

TD Cowen analyst Charles Rhyee maintains DarioHealth (NASDAQ:DRIO) with a Hold and lowers the price target from $11 to $8.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 17, 2026, 11:36 AMBenzinga Newsdesk
DarioHealth Secures New Jersey Health Plan Contract Through Amwell Partnership; Dario's Cardiometabolic Suite Launch Set For Q1 2027
Agreement secured through channel partner Amwell significantly expands Dario's reach through its channel distribution strategyProgram for Dario's cardiometabolic suite and provider-backed care expected to launch
DRIO
SEC EDGARSep 4, 2026, 8:05 PMSEC EDGAR
8-K filing — DarioHealth Corp. (DRIO)
Filed: 2026-09-04 AccNo: 0001104659-26-105495 Size: 186 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
DRIO
BenzingaAug 19, 2026, 3:45 PMBenzinga Newsdesk
Alliance Global Partners Initiates Coverage On DarioHealth with Buy Rating, Announces Price Target of $12
Alliance Global Partners analyst Scott Henry initiates coverage on DarioHealth (NASDAQ:DRIO) with a Buy rating and announces Price Target of $12.
DRIO